203 related articles for article (PubMed ID: 19522698)
21. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.
Willmott LJ; Monk BJ
Expert Rev Anticancer Ther; 2009 Jul; 9(7):895-903. PubMed ID: 19589029
[TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer.
Wu J; Chen C; Zhao KN
Curr Cancer Drug Targets; 2013 Feb; 13(2):143-56. PubMed ID: 23297827
[TBL] [Abstract][Full Text] [Related]
23. Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer.
Crowley FJ; O'Cearbhaill RE; Collins DC
Cancer Treat Rev; 2021 Jul; 98():102225. PubMed ID: 34082256
[TBL] [Abstract][Full Text] [Related]
24. New pharmacotherapy options for cervical cancer.
Dueñas-Gonzalez A; Cetina L; Coronel J; Cano C; Dolores R
Expert Opin Pharmacother; 2014 Jan; 15(1):51-60. PubMed ID: 24206031
[TBL] [Abstract][Full Text] [Related]
25. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
Martínez P; Del Campo JM
Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
[TBL] [Abstract][Full Text] [Related]
26. [Current methods of chemoradiotherapy for locally advanced cervical cancer. Options for reduction of side-effects].
Póti Z; Mayer A
Orv Hetil; 2013 May; 154(21):803-9. PubMed ID: 23692874
[TBL] [Abstract][Full Text] [Related]
27. [The guidelines for diagnostics and treatment of cervical cancer].
Inciūra A; Juozaityte E
Medicina (Kaunas); 2004; 40(4):394-403. PubMed ID: 15111756
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
29. Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.
Longoria TC; Tewari KS
Drugs; 2015 Nov; 75(16):1853-65. PubMed ID: 26474780
[TBL] [Abstract][Full Text] [Related]
30. [Targeted therapy in locally and metastatic recurrent cervical cancers].
Geiss R; De La Motte Rouge T; Dubot C; Leary A; Lhommé C; Pautier P; Scholl S; Rodrigues MJ
Bull Cancer; 2014; 101(7-8):748-55. PubMed ID: 25091657
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for the treatment of cervical cancer.
Serrano-Olvera A; Cetina L; Coronel J; Dueñas-González A
Expert Opin Emerg Drugs; 2015 Jun; 20(2):165-82. PubMed ID: 25578210
[TBL] [Abstract][Full Text] [Related]
32. Topotecan in cervical cancer.
Ackermann S; Beckmann MW; Thiel F; Bogenrieder T
Int J Gynecol Cancer; 2007; 17(6):1215-23. PubMed ID: 17997795
[TBL] [Abstract][Full Text] [Related]
33. Current and potential treatments for cervical cancer.
Yee GP; de Souza P; Khachigian LM
Curr Cancer Drug Targets; 2013 Feb; 13(2):205-20. PubMed ID: 23259831
[TBL] [Abstract][Full Text] [Related]
34. [Medical treatment of metastatic or recurrent cancer of the cervix].
de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
36. The role of topotecan in the treatment of advanced cervical cancer.
Fiorica JV
Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S16-21. PubMed ID: 13129491
[TBL] [Abstract][Full Text] [Related]
37. Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer.
Wolford JE; Tewari KS
Expert Opin Drug Discov; 2018 May; 13(5):445-457. PubMed ID: 29463131
[TBL] [Abstract][Full Text] [Related]
38. HIV Infection and Survival Among Women With Cervical Cancer.
Dryden-Peterson S; Bvochora-Nsingo M; Suneja G; Efstathiou JA; Grover S; Chiyapo S; Ramogola-Masire D; Kebabonye-Pusoentsi M; Clayman R; Mapes AC; Tapela N; Asmelash A; Medhin H; Viswanathan AN; Russell AH; Lin LL; Kayembe MKA; Mmalane M; Randall TC; Chabner B; Lockman S
J Clin Oncol; 2016 Nov; 34(31):3749-3757. PubMed ID: 27573661
[TBL] [Abstract][Full Text] [Related]
39. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology.
Eskander RN; Tewari KS
Future Oncol; 2015; 11(6):909-22. PubMed ID: 25760973
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy for advanced or recurrent cervical cancer.
Kamura T; Ushijima K
Taiwan J Obstet Gynecol; 2013 Jun; 52(2):161-4. PubMed ID: 23915846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
